abstract |
The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A 11 -A 12 -A 13 -Gly-Ser-A 14 -Phe-Leu-A 15 -A 16 -A 17 -A 18 , wherein each of A 11 , A 12 , and A 13 is independently absent, an amino acid, or an amino protecting group; each of A 15 , A 16 , A 17 , and A 18 is independently absent or an amino acid; and A 14 is a serine conjugated with a —C(O)C 1 -C 20 alky or a diaminopropionic acid conjugated with a —C(O)C 1 -C 20 alkyl group, provided that at least one of A 11 , A 12 , or A 13 is present. |